Myriad Genetics News

Jolie revealed last week that she chose to undergo a double mastectomy after testing positive for the BRCA1 mutation.

THE US Supreme Court recently began deliberations in a case that highlights a deeply problematic issue concerning intellectual property rights.

A new genetic test to gauge the aggressiveness of prostate cancer may help tens of thousands of men each year decide whether they need to treat their cancer right away or can safely monitor it.

Earlier this week, Angelina Jolie wrote a heartfelt op-ed in The New York Times about her decision to undergo a preventive double mastectomy.

EXPOSED: Angelina Jolie part of a clever corporate scheme to protect billions in BRCA gene patents, influence Supreme Court decision Angelina Jolie's announcement of undergoing a double mastectomy even though she had no breast cancer is not the innocent, spontaneous, "heroic choice" that has been portrayed in the mainstream media.

Earlier this week the actress revealed that she underwent a preventative double mastectomy after she tested positive for a gene that indicates an increased risk for breast and ovarian cancer.

The biggest concern of the biotechnology industry caused by the impending Supreme Court decision in the AMP v. Myriad Genetics case is the threat to existing patents having claims to isolated human DNA that a negative decision from the Court could raise.

Angelina Jolie's decision to undergo a preventative double mastectomy has put the spotlight on Myriad Genetics, the only company in the world that conducts genetic tests for breast cancer.

On April 15, in the case of The Association for Molecular Pathology vs. Myriad Genetics, Inc.

Angelina Jolie's double mastectomy revelation had the unintended side-effect of boosting the share price for the biotech firm that owns the patent to her "breast cancer gene," highlighting an ongoing US Supreme Court battle over the right to patent life.

The actress revealed in a New York Times op-ed that she underwent the surgery to prevent cancer.

Actress Angelina Jolie's announcement on Tuesday that she underwent a double mastectomy following genetic testing underscores the broad implications of an upcoming U.S. Supreme Court decision on whether corporations can own human genes.

Angelina Jolie, named the highest- paid actress in Hollywood by Forbes in 2011, said she had a double mastectomy after learning she has a gene mutation linked to breast cancer, the disease that killed her mother at age 56.

SNE - Sony Corp - Big prints in Sony Corp. call and put options this morning pushed the consumer electronics maker onto our 'hot by options volume' market scanner in the early going on Monday, with overall volume up above 21,000 contracts versus the stock's average daily volume of roughly 8,000 contracts.

The Supreme Court recently began deliberations in a case that highlights a deeply problematic issue concerning intellectual property rights: Can human genes - your genes - be patented? Put another way, should someone essentially be permitted to own the right, say, to test whether you have a set of genes that imply a higher than 50 percent ... (more)

The firm currently has a $34.00 target price on the stock, up from their previous target price of $27.00. Shares of Myriad Genetics traded up 8.60% during mid-day trading on Wednesday, hitting $33.10. Myriad Genetics has a 52 week low of $22.02 and a 52 week high of $31.80. The stock's 50-day moving average is currently $25.6. The company has a ... (more)

's stock had its "neutral" rating reiterated by Zacks in a research note issued to investors on Friday, StockRatingsNetwork reports.

Myriad Genetics has isolated a human DNA sequence used for tests to detect whether women are at a higher risk for breast or ovarian cancer.

Shares of Myriad Genetics opened at 30.63 on Thursday. Myriad Genetics has a 52 week low of $22.02 and a 52 week high of $31.80. The stock's 50-day moving average is currently $25.6. The company has a market cap of $2.468 billion and a P/E ratio of 20.99. Myriad Genetics last issued its quarterly earnings data on Tuesday, May 7th.

Check below for free stories on FIO;WFM;EA;DAL;BBRY;AOL;MYGN;VCLK;CTSH;AXLL;Z;SYMC;SODA the last two weeks.